Rare Diseases

Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race
····

Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race

Arrowhead Pharmaceuticals shares rose 5% to $78.68 Tuesday after new plozasiran data supported use in patients with moderate kidney or liver issues. The company’s market cap reached $11.2 billion. Arrowhead reported $73.7 million in quarterly revenue and a net loss of $132.7 million. Rival Sobi released Phase 3 data on olezarsen the same day.
May 27, 2026

Stock Market Today

  • Temple & Webster (ASX:TPW) Shares Fall 75%: Is It a Buy Amidst Market Challenges?
    May 26, 2026, 7:58 PM EDT. Temple & Webster Group Ltd (ASX:TPW) shares have plunged roughly 75% over 12 months due to slowed housing demand, rising costs, and consumer tightening. Despite a recent 19.8% revenue rise, profits tumbled 36%, and gross margins slipped from 32.4% to 30.5%, impacted by high customer acquisition costs and expansion efforts. The company's post-earnings 25% share drop highlights investor concerns. However, a May 2026 trading update showed improved profitability after strategic adjustments. Incoming CEO Susie Sugden's marketing expertise may steer growth amid ongoing challenges. Temple & Webster remains a speculative buy for patient investors seeking long-term gains from the growing Australian furniture market, despite near-term volatility.